Compound Evidence File
#EC-2026-0391
Prednisone
Filed under Oral Tablets. The bureau holds 158 laboratory returns for this compound from 51 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
51 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 7 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Dec 2025 | 26 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Mar 2026 | 18 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Apr 2026 | 9 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 18 May 2026 | 11 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 26 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Jan 2026 | 3 May 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Feb 2026 | 2 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Jun 2026 | 17 Jun 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jul 2025 | 3 Jul 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 3 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 9.9 | 23 Mar 2026 | 13 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Jan 2026 | 14 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Jan 2026 | 21 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Dec 2025 | 23 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 28 May 2026 | 10 Aug 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Jun 2026 | 7 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 28 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 17 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Apr 2026 | 17 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 22 Mar 2026 | 11 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 12 May 2026 | 19 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 9.0 | 7.5 | 9.9 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.9 | 8.8 | 9.0 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.8 | 7.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.4 | 7.4 | 9.2 | 24 May 2026 | 24 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 7 | 8.4 | 7.2 | 10.0 | 6 May 2025 | 20 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.3 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 8.2 | 8.2 | 8.2 | 6 May 2025 | 6 May 2025 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 7.6 | 7.5 | 7.7 | 28 Mar 2025 | 19 Jan 2026 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 7.6 | 7.6 | 7.6 | 21 May 2025 | 21 May 2025 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 3 | 7.2 | 5.9 | 8.6 | 17 Dec 2024 | 20 May 2026 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 7.2 | 7.2 | 7.2 | 2 Apr 2025 | 2 Apr 2025 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 7.1 | 7.1 | 7.1 | 3 Jul 2025 | 3 Jul 2025 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 2 | 7.0 | 5.9 | 8.1 | 25 Apr 2025 | 24 May 2026 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 7.0 | 7.0 | 7.0 | 3 Jul 2025 | 3 Jul 2025 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 7.0 | 7.0 | 7.0 | 2 Jul 2025 | 2 Jul 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 6.6 | 6.6 | 6.6 | 7 May 2025 | 7 May 2025 |
| OupeptideCASE #VI-2026-0435 | X | 9 | 6.1 | 4.7 | 7.4 | 2 Apr 2025 | 25 May 2026 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 6.0 | 6.0 | 6.0 | 13 Feb 2025 | 13 Feb 2025 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 3 | 5.9 | 4.8 | 7.1 | 6 May 2025 | 21 May 2026 |
| TydesCASE #VI-2026-0493 | X | 4 | 5.7 | 4.9 | 7.1 | 21 May 2025 | 21 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 5.3 | 5.3 | 5.3 | 28 Mar 2025 | 28 Mar 2025 |
| Elite Research USACASE #VI-2026-0267 | X | 3 | 5.0 | 3.3 | 6.7 | 8 Jul 2025 | 25 May 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 4.9 | 4.9 | 4.9 | 25 Apr 2025 | 25 Apr 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 4.7 | 4.7 | 4.7 | 27 Feb 2025 | 27 Feb 2025 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 4.2 | 4.2 | 4.2 | 16 Mar 2025 | 16 Mar 2025 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 | 24 Apr 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
Open any subject to view the batch-level evidence for Prednisone alone.